
Loading, please wait...

Loading, please wait...

Researchers recently explored how Boswellia dalzielii brain enzymes modulation could pave the way for new neuroprotective therapies. Traditional African medicine has long utilized Boswellia dalzielii to manage cognitive and neurological issues. However, the scientific basis for these effects required rigorous in vitro validation. A recent study published in BMC Complementary Medicine and Therapies investigated how different plant parts affect enzymes crucial for maintaining cognitive health.
The study found that the stem bark extract was the most potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). These enzymes break down acetylcholine, a neurotransmitter vital for memory. By inhibiting these enzymes, the extract may help maintain higher acetylcholine levels. Consequently, this mechanism mirrors the action of standard dementia medications. Additionally, the root bark extract showed the strongest inhibition of monoamine oxidase (MAO), which is a key target in managing depression and Parkinson's disease.
Furthermore, the extracts influenced other enzymatic pathways. They inhibited ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) and ecto-5'-nucleotidase. These enzymes regulate purinergic signaling, which plays a role in neuroinflammation and cellular energy balance. The stem bark extract also moderately enhanced Na⁺/K⁺-ATPase activity. This modulation helps maintain the ionic gradients necessary for proper neuronal firing. Overall, the presence of stilbenoids across all plant parts likely contributes to these multi-target effects.
While these results are preliminary, they provide a strong foundation for future research. Specifically, the stem bark's potency suggests it could be a primary candidate for isolating bioactive compounds. The multi-enzyme inhibitory profile indicates that Boswellia dalzielii might offer a holistic approach to complex brain disorders. Future in vivo studies are necessary to confirm if these laboratory findings translate into clinical benefits for patients with Alzheimer's or other cognitive impairments.
According to the study, the stem bark extract demonstrated the most potent inhibition of enzymes related to memory and neuronal function, followed by the root and leaf extracts.
The stem bark extract showed inhibitory potency against cholinesterase enzymes that was comparable to Prostigmine, a standard pharmaceutical inhibitor, in laboratory settings.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A study finds that Boswellia dalzielii extracts, particularly the stem bark, inhibit key enzymes like AChE and MAO, suggesting potential neuroprotective use...
8 months ago

Co-administering antiseizure medications and DOACs frequently causes pharmacokinetic interactions, subtherapeutic drug levels, and thromboembolic failures. This review highlights enzyme induction risks, unpredictable outcomes with levetiracetam, and the vital role of therapeutic drug monitoring.
Today

Demanding exhaustive hormonal profiling can inadvertently discourage clinical studies involving females. Methodological standards must align with the specific scientific question to expand, not restrict, equitable evidence for women.
Today

An elderly man with partially repaired Tetralogy of Fallot presented with STEMI caused by coronary embolism rather than atherosclerosis. Successful treatment with sustained mechanical aspiration thrombectomy underscores the vital need for high clinical vigilance in adult congenital heart disease.
Today

A comparative review of tension band wiring and intramedullary screw fixation in thumb metacarpophalangeal arthrodesis, evaluating union rates, hardware complications, and clinical outcomes.
Today

Following regulatory scrutiny from FSSAI regarding promotional representations and lean muscle preservation claims, Dr. Reddy's Laboratories and Nestlé Health Science are currently reviewing the branding and marketing strategy for their joint nutritional supplement Celevida GLP+.
Today